Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07427628 · ClinicalTrials.gov registry record · Phase 1
A Proof-of-concept Trial to EvaluAte the efficaCy and Safety Of Cell Therapy TRX103 in Patients With Active, Non-infectious Uveitis
A Phase 1 study, sponsored by Quan Dong Nguyen.
- Not yet
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT07427628 is a Phase 1 study that has not yet begun recruiting, run by Quan Dong Nguyen. The registered enrollment target is 18 participants.
The verdict
NCT07427628, a Phase 1 study, has not yet begun recruiting, sponsored by Quan Dong Nguyen.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this Phase 1, first in uveitis open-label study is to assess the safety and tolerability of TRX-103 in patients with non infectious uveitis (NIU). It is anticipated that up to 18 Subjects will be enrolled during a 18-24 month enrollment period. TRX-103 will be infused one time.
Interventions
- BIOLOGICAL TRX103
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2026-03 |
| Est. Completion | 2028-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07427628
The ClinicalTrials.gov registry entry for NCT07427628 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Quan Dong Nguyen, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TRX103 is the first listed.
NCT07427628 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07427628 about?
NCT07427628 is a clinical study titled "A Proof-of-concept Trial to EvaluAte the efficaCy and Safety Of Cell Therapy TRX103 in Patients With Active, Non-infectious Uveitis". The purpose of this Phase 1, first in uveitis open-label study is to assess the safety and tolerability of TRX-103 in patients with non infectious uveitis (NIU). It is anticipated that up to 18 Subjects will be enrolled during a 18-24 month enrollment period. TRX-103 will be infused one time.
What is the current status of trial NCT07427628?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2026-03. Estimated completion is 2028-12.
What interventions are being tested in trial NCT07427628?
The interventions under investigation include: TRX103 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07427628?
This trial is sponsored by Quan Dong Nguyen, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.